RegMed Forum 2027: From pluripotent stem cells (PSCs) to Next-Generation Gene and Cell Therapies - Save the Date
Human pluripotent stem cells (hPSCs) have become a key platform for regenerative medicine, enabling disease modeling, drug discovery, and the development of advanced gene- and cell-based therapies. Rapid progress in stem cell technologies is accelerating the generation, differentiation, and clinical translation of hPSC-derived products.
The RegMed Forum 2027 will showcase cutting-edge developments in hPSC-based regenerative therapies, covering novel therapeutic approaches, cell differentiation and maturation, GMP-compliant manufacturing, quality control, and regulatory aspects. Special emphasis will be placed on strategies to improve the safety, efficacy, scalability, and accessibility of next-generation therapies.
Bringing together experts from academia, start-ups, and industry, the Forum aims to promote interdisciplinary exchange on the clinical translation of advanced therapeutic approaches, including ATMPs, advanced medical devices, and combined products. The Forum seeks to encourage strategic partnerships and accelerate the translation of scientific discoveries into clinical and commercial applications. Through scientific sessions and networking opportunities, participants will explore current challenges and future opportunities in the rapidly evolving field of gene- and cell-based therapies.
An accompanying industry exhibition will provide a platform for companies and technology providers to present innovative tools, services, and therapeutic solutions.
When:
- February 11 2027 | 01:00 pm - 08:00 pm
- February 12 2027 | 09:00 am - 02:00 pm
Industry Exhibition
Are you interested in participating in our industry exhibition at the upcoming RegMed Forum on 11-12 February 2027? For further information, please contact Anne-Christin Schöne.
Confirmed speakers so far:
- Annette Künkele-Langer - Charité Universitätsklinik Berlin
- Barbara Ludwig - Universitätsklinikum Carl Gustav Carus Dresden, Medizinische Fakultät Dresden, TU Dresden
- Eric Metzer-Bräuchle - MyoPax GmbH
- Daniel Ortmann - Berlin Institute of Health – Center for Regenerative Therapies
- Olaf Strauß - Charité Universitätsklinik Berlin
- Wolfram-Hubertus Zimmermann - Department of Pharmacology and Toxicology University Medical Center Goettingen
- Robert Zweigerdt - Medizinische Hochschule Hannover
Further information will follow shortly.
What to expect?
- Talks & panel discussions with different stakeholders.
- Onsite networking opportunity.
- Industry exhibition to present your products and services
You should attend if you...
- Develop or manufacture innovative therapeutic approaches
- Provide services or products that support the field of therapy development, manufacturing and translation
- Want to learn about academic vs. industrial settings for therapy development
- Expand your knowledge about clinical trials innovative products
- Explore new partnership opportunities for your institution
- Wish to expand your professional network
Who will be attending?
Academic researchers, manufacturers, pharma companies and spin-offs/start-ups interested in clinical translation of innovative therapies.
Registration:
- Participation fee: 50,00 €
- Student participation fee: 20,00 €
For more information please click here.
This event is organized by the BIH Center for Regenerative Therapies at Charité, Berlin Partner, HealthCapital Berlin-Brandenburg, as well as the German Stem Cell Network (GSCN) e.V.
